Busting the PoseBusters v3: AI Docking Software ArtiDock Beats Industry’s State of the Art in Speed and Accuracy

We at Receptor.AI are excited to present the next important milestone in the development of our next-generation AI docking model, …

Continue ›››

In an Industry First, Veeva Migrates Study Portfolio of Top 20 Biopharmas to Vault EDC

Veeva Systems, a prominent player in cloud-based software for the global life sciences industry, has successfully migrated a significant portfolio …

Continue ›››

Innovative Approach to Combat Arthritis: Mesenbio's Stem Cell Therapy

Mesenbio, a pioneering biotechnology firm emerging from the University of York, has recently secured a significant £1.4 million investment. This …

Continue ›››

10 Major Biotech Funding Rounds of 2023

In 2023, the venture capital (VC) landscape witnessed significant activity, providing crucial support to the biotech sector amidst a volatile …

Continue ›››

Conducting a Cellular Symphony With Life Saving Combination Therapies

I always think of the Jeff Goldblum quote in Jurassic Park where he says "life finds a way" when I …

Continue ›››

Playing Chess Against Cancer: A Pharmaceutical, Biotechnological, and Clinical Guide to Modern Day Oncologic Treatment Cartography

We are witnessing a revolution in cancer therapeutics that is truly bewildering. The number of novel drugs with unique mechanisms …

Continue ›››

Quarterbacking a Patient's Fight Against Cancer

In the incredibly competitive world of drug development, comprehensive precision, and healthtech, every strategic control point is essential. Over the …

Continue ›››

Drowning in Data: A Data Science Primer for a Translational Scientist

In 1945 the volume of human knowledge doubled every 25 years. Now, that number is 12 hours [1]. With our …

Continue ›››

Predicting a Patient’s Future with a Crystal Ball Comprised of Cell-free DNA

Chapter 1 of a 3-chapter Hitchhiker’s guide to cell-free DNA for travelers of all backgrounds and expertise. Even though I’ve …

Continue ›››

Hunting Cancer Before It Can Hunt You: A Bird's Eye View of Cell-Free DNA Market Trends

Chapter 2 of a Hitchhiker's Guide to Cell-Free DNA. By the end of 2022, there will be an estimated 609,360 …

Continue ›››

Wielding New Cancer Weapons Forged in Cell-Free DNA: A Wake Up Call For The Entire Biotech Industry

Advances in computational biology, precision medicine, artificial intelligence/machine learning, etc., are launching us into a world where strategic control points …

Continue ›››

A Proof-of-Concept Study Towards Novel ALS Therapy

Verge Genomics, a clinical-stage biotechnology company, has just initiated a Phase 1b proof-of-concept study for VRG50635, a drug developed for …

Continue ›››